6 news items
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
PRCT
13 May 24
tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant
PROCEPT BioRobotics Announces Real-World, Long-Term Data Demonstrate Sustained Benefits Of Aquablation Therapy For Men With Benign Prostatic Hyperplasia
PRCT
6 May 24
therapy has durable outcomes and low retreatment rates for the treatment of LUTS/BPH independently of prostate volume between 30-150 ml prostates
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
PRCT
1 May 24
therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
PRCT
4 Apr 24
symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
PRCT
2 Apr 24
that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which
tevszxomkekfax88gjtv
PRCT
27 Feb 24
from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed
- Prev
- 1
- Next